| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Arctigenin 4'-O-β-gentiobioside targets multiple cellular pathways involved in inflammation, oxidative stress, and cell signaling. As a lignan glycoside, it is related to arctigenin, which has antioxidant, anti-tumor, anti-inflammatory, and anti-viral activities. The compound modulates cell function and signal transduction. Its biological activities include anti-inflammatory, anti-tumor, and neuroprotective effects. Further studies are needed to fully characterize its molecular targets.
|
|---|---|
| ln Vitro |
In vitro, Arctigenin 4'-O-β-gentiobioside has demonstrated various biological activities. The compound exhibits anti-inflammatory, anti-tumor, and neuroprotective effects in cell-based assays. It modulates cell function and signal transduction. Related compound arctigenin has shown antioxidant, anti-tumor, anti-inflammatory, and anti-viral activities. The compound’s effects on various cell types have been investigated in preclinical studies. Further in vitro studies are ongoing to fully characterize its bioactivity.
|
| ln Vivo |
In vivo, Arctigenin 4'-O-β-gentiobioside has been studied in preclinical models. Related compound arctigenin has shown activity in models of metabolic disorders and central nervous system dysfunction. The compound’s anti-inflammatory, anti-tumor, and neuroprotective effects have been evaluated in animal models. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties. The compound is typically administered orally in preclinical studies.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Arctigenin 4'-O-β-gentiobioside involve measuring its effects on various cellular targets. The compound’s anti-inflammatory activity is assessed by measuring cytokine production or NF-κB activation. Anti-tumor activity is evaluated by assessing cell proliferation and apoptosis. Neuroprotective effects are measured by assessing neuronal cell survival and oxidative stress markers. Assays are performed in appropriate buffer systems with positive controls. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for Arctigenin 4'-O-β-gentiobioside are conducted in various cell lines. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Cell viability is assessed by MTT or CCK-8 assays. Apoptosis is evaluated by Annexin V/PI staining and caspase activity assays. Inflammatory markers are measured by ELISA or Western blot. Signal transduction pathways are analyzed by Western blot or reporter gene assays. Experiments are performed in triplicate with appropriate controls.
|
| Animal Protocol |
In vivo animal studies for Arctigenin 4'-O-β-gentiobioside are conducted in rodent models of inflammation, cancer, and neurological disorders. Animals are treated with the compound via oral administration or intraperitoneal injection. Disease progression is monitored by appropriate endpoints. For anti-inflammatory studies, animal models of inflammation are used. For anti-tumor studies, tumor-bearing mice are used. For neuroprotection, models of neurodegeneration are employed. Dosing regimens are optimized based on pharmacokinetic data. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis.
|
| ADME/Pharmacokinetics |
Arctigenin 4'-O-β-gentiobioside (MW 696.69 g/mol, C33H44O16) is a large lignan glycoside. The compound is a natural product derived from Arctium lappa and Trachelospermum jasminoides. Its large molecular size may affect oral bioavailability. The compound is metabolized by deglycosylation to release the active aglycone arctigenin. Pharmacokinetic parameters such as Cmax, Tmax, and half-life would be determined in species-specific studies. The compound shows stability under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Arctigenin 4'-O-β-gentiobioside is generally well-tolerated in preclinical studies. The compound is a natural lignan glycoside derived from edible plants. Related compound arctigenin has been studied for its safety profile. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| Additional Infomation |
Reports indicate that arctiin 4'-O-β-gentiobiose has been found in Trachelospermum jasminoides, and relevant data are available for reference.
Arctigenin 4'-O-β-gentiobioside is a natural compound derived from Arctium lappa (greater burdock) and Trachelospermum jasminoides. It is a lignan glycoside with diverse pharmacological activities including anti-inflammatory, anti-tumor, and neuroprotective effects. The compound modulates cell function and signal transduction. Related compound arctigenin has antioxidant, anti-tumor, anti-inflammatory, and anti-viral activities. Preclinical studies have investigated its biological effects. All applications are limited to non-human research use. |
| Molecular Formula |
C33H44O16
|
|---|---|
| Molecular Weight |
696.6929
|
| Exact Mass |
696.262
|
| CAS # |
41682-24-0
|
| PubChem CID |
14681436
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
926.1±65.0 °C at 760 mmHg
|
| Melting Point |
174-176 °C
|
| Flash Point |
291.0±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.638
|
| LogP |
-0.55
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
49
|
| Complexity |
1040
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C1(C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1)OC1C(OC)=CC(CC2C(CC3C=C(OC)C(OC)=CC=3)COC2=O)=CC=1
|
| InChi Key |
FEQSYBHDHIPRKS-QWNZGVGBSA-N
|
| InChi Code |
InChI=1S/C33H44O16/c1-42-19-6-4-15(10-21(19)43-2)8-17-13-45-31(41)18(17)9-16-5-7-20(22(11-16)44-3)47-33-30(40)28(38)26(36)24(49-33)14-46-32-29(39)27(37)25(35)23(12-34)48-32/h4-7,10-11,17-18,23-30,32-40H,8-9,12-14H2,1-3H3/t17-,18+,23+,24+,25+,26+,27-,28-,29+,30+,32+,33+/m0/s1
|
| Chemical Name |
(3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyphenyl]methyl]oxolan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4354 mL | 7.1768 mL | 14.3536 mL | |
| 5 mM | 0.2871 mL | 1.4354 mL | 2.8707 mL | |
| 10 mM | 0.1435 mL | 0.7177 mL | 1.4354 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
